While PARPi are generally inefficient against HR-proficient tumors, it was shown that inhibiting the HR pathway with RAD51 shRNA [51] or with small-molecule inhibitors disrupting the RAD51/BRCA2 interface [52] sensitized cancer cells to PARPi. This evidence concerns the gene RAD51 and cancer.